KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Oncology
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| amg 510 | AMGEN INC (AMGN) |
Frequently asked questions
How many drugs are in development for KRAS p, G12c Mutated /Advanced Metastatic NSCLC?
BioSniper tracks 1 drug in development for KRAS p, G12c Mutated /Advanced Metastatic NSCLC across 1 company.
How many clinical trials target KRAS p, G12c Mutated /Advanced Metastatic NSCLC?
There are 1 clinical trial targeting KRAS p, G12c Mutated /Advanced Metastatic NSCLC tracked by BioSniper.
Deep-dive into KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis